Literature DB >> 9462162

Diagnosis and treatment of amyloidosis.

P N Hawkins1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9462162      PMCID： PMC1752281          DOI： 10.1136/ard.56.11.631

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  20 in total

Review 1.  Amyloidosis in juvenile chronic arthritis.

Authors:  J David
Journal:  Clin Exp Rheumatol       Date:  1991 Jan-Feb       Impact factor: 4.473

2.  Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis.

Authors:  D R Booth; M Sunde; V Bellotti; C V Robinson; W L Hutchinson; P E Fraser; P N Hawkins; C M Dobson; S E Radford; C C Blake; M B Pepys
Journal:  Nature       Date:  1997-02-27       Impact factor: 49.962

3.  Fifteen years' experience with renal transplantation in systemic amyloidosis.

Authors:  A Hartmann; H Holdaas; P Fauchald; K P Nordal; K J Berg; T Talseth; T Leivestad; I B Brekke; A Flatmark
Journal:  Transpl Int       Date:  1992-03       Impact factor: 3.782

4.  Amyloidosis in juvenile chronic polyarthritis.

Authors:  T J Schnitzer; B M Ansell
Journal:  Arthritis Rheum       Date:  1977-03

5.  Factor X deficiency in primary amyloidosis: resolution after splenectomy.

Authors:  P R Greipp; R A Kyle; E J Bowie
Journal:  N Engl J Med       Date:  1979-11-08       Impact factor: 91.245

6.  Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis.

Authors:  G Holmgren; B G Ericzon; C G Groth; L Steen; O Suhr; O Andersen; B G Wallin; A Seymour; S Richardson; P N Hawkins
Journal:  Lancet       Date:  1993-05-01       Impact factor: 79.321

7.  Response rates and survival in primary systemic amyloidosis.

Authors:  M A Gertz; R A Kyle; P R Greipp
Journal:  Blood       Date:  1991-01-15       Impact factor: 22.113

Review 8.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616

9.  Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.

Authors:  P N Hawkins; J P Lavender; M B Pepys
Journal:  N Engl J Med       Date:  1990-08-23       Impact factor: 91.245

10.  Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis.

Authors:  P N Hawkins; S Richardson; D M Vigushin; J David; C R Kelsey; R E Gray; M A Hall; P Woo; J P Lavender; M B Pepys
Journal:  Arthritis Rheum       Date:  1993-06
View more
  3 in total

1.  Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis.

Authors:  M A Gertz; M Q Lacy; J A Lust; P R Greipp; T E Witzig; R A Kyle
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 2.  Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.

Authors:  Cecilia Mercieca; Irene E van der Horst-Bruinsma; Andrew A Borg
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

3.  Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients.

Authors:  Senol Kobak; Fahrettin Oksel; Yasemin Kabasakal; Eker Doganavsargil
Journal:  Clin Rheumatol       Date:  2007-07-05       Impact factor: 2.980
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.